Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation

International Journal of Cancer

Volumn 125, Issue 12, 2009, Pages 2879-2886

  Kubota, Takeshi ^a   Taiyoh, Hiroaki ^a   Matsumura, Atsushi ^a   Murayama, Yasutoshi ^a   Ichikawa, Daisuke ^a   Okamoto, Kazuma ^a   Fujiwara, Hitoshi ^a   Ikoma, Hisashi ^a   Nakanishi, Masayoshi ^a   Kikuchi, Shojiro ^a   Ochiai, Toshiya ^a   Sakakura, Chouhei ^a   Kokuba, Yukihito ^a   Sonoyama, Teruhisa ^a   Suzuki, Yoshinori ^b   Matsumoto, Kunio ^b   Nakamura, Toshikazu ^c   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Antiangiogenesis; c Met; Cytotoxic T lymphocyte; Hepatocyte growth factor; NK4

Indexed keywords

ANGIOGENESIS INHIBITOR; NK4; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER INHIBITION; CARCINOGENICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR REGRESSION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 72449192839     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24735     Document Type: Article

References (24)

1. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-443 (Pubitemid 19277521)
2. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996;119:591-600. (Pubitemid 26131762)
3. Jiang WG, Hiscox S. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol Histopathol 1997;12:537-555 (Pubitemid 27240325)
4. Bardelli A, Longati P, Albero D, Goruppi S, Schneider C, Ponzetto C, Comoglio PM. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996;15:6205-6212 (Pubitemid 26397893)
5. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, Isner JM. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998;97:381-390 (Pubitemid 28074339)
6. Bottaro DP, Rubin JS, Faletto DL, Chan AMI, Kmiecik TE, Vande Woude GF, Aaronson SA. Idetification of hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-804 (Pubitemid 21926175)
7. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S, Plebani M, Gespach C, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-154
8. Otte JM, Schmitz F, Kiehne K, Stechele HU, Banasiewicz T, Krokowicz P, Nakamura T, Folsch UR, Herzig K. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 2000;61:237-246 (Pubitemid 30418224)
9. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6. (Pubitemid 28037188)
10. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000;60:6737-6743
11. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998;17:3045-3054 (Pubitemid 29012208)
12. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K, Nakamura T. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001;61:7518-7524 (Pubitemid 32995042)
13. Saimura M, Nagai E, Mizumoto K, Maehara N, Minamishima YA, Katano M, Matsumoto K, Nakamura T, Tanaka M. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res 2002;8:3243-3249 (Pubitemid 35155037)
14. Kubota T, Fujiwara H, Amaike H, Takashima K, Inada S, Atsuji K, Yoshimura M, Matsumoto K, Nakamura T, Yamagishi H. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. Cancer Sci 2004;95:321-327 (Pubitemid 38519472)
15. Ueda K, Iwahashi M, Matsuura I, Nakamori M, Nakamura M, Ojima T, Naka T, Ishida K, Matsumoto K, Nakamura T, Yamaue H. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur J Cancer 2004;40:2135-2142 (Pubitemid 39165548)
16. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965 (Pubitemid 24196166)
17. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 1995;3:783-791 (Pubitemid 26091151)
18. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997;186:65-70. (Pubitemid 27304848)
19. Kern DE, Klamet JP, Jensen MC, Greenberg PD. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol 1986;136:4303-4310
20. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89 (Pubitemid 28150594)
21. Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998;161:4467-4471 (Pubitemid 28492012)
22. Holmgren L, Michael S, O'reilly J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1996;1:149-153
23. Kikuchi T, Maemondo M, Narumi K, Matsumoto K, Nakamura T, Nukiwa T. Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells. Blood 2002;100:3950-3959 (Pubitemid 35396860)
24. Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/Met signaling in cancer. Clin Cancer Res 2008;14:5941-5946